Register Here Membership Login
Equilibrium Healthcare
Clinical Trials

Clinically tested for real results

Tri-HELIX COMPLEX™ is validated through rigorous, placebo-controlled clinical trials that reveal measurable, visible improvements across hair health, skin performance, strength, and joint mobility.

Clinically Proven Hair Health

Thicker hair, stronger roots.

To validate the effectiveness of Tri-HELIX COMPLEX™, a placebo-controlled clinical study was conducted to assess its impact on hair thickness and scalp metabolism. Designed to meet the highest scientific standards, this trial offers powerful insights into the proven benefits of our advanced hair health formulation.

Placebo-Controlled Trial

A 16-week, placebo-controlled study with 44 healthy women aged 39 to 75 showed measurable improvements in hair thickness and scalp metabolism—highlighting the real, visible results of this scientifically formulated complex.

Mechanical Strength & Density

Clinical studies proved the effects of Tri-HELIX COMPLEX™ on the mechanical strength of hair and skin density. Changes were measured after 90 days of supplementation relative to baseline.

Diverse Participants

The 90-day study included 30 healthy women aged 45–60 with diverse hair types, each using daily supplementation of Tri-HELIX COMPLEX™.

16 Weeks

Placebo-controlled, hair thickness study.

90 Days

Mechanical strength & skin density evaluation.

44 Women

Participants aged 39–75 in the primary trial.
Clinically Proven Skin & Beauty Performance

Visible improvements in skin structure.

In a gold-standard double-blind, placebo-controlled study, the power of Tri-HELIX COMPLEX™ was put to the test, targeting fine lines, collagen production, and skin elasticity.

Gold-Standard Protocol

114 women aged 45–65 participated in the trial, receiving either Tri-HELIX COMPLEX™ or a placebo daily for 8 weeks.

Objective Measurements

Researchers measured wrinkle depth, skin firmness, and collagen markers at the start, midpoint, and end of treatment — plus four weeks after stopping.

Clinically Significant Results

The study delivered clinically significant improvements in eye wrinkles and skin structure, proving Tri-HELIX COMPLEX™ delivers real results.

Clinically Proven Strength Enhancement

Stronger bodies, healthier composition.

In a comprehensive study, the effects of progressive resistance training on body composition and muscle strength were investigated alongside daily Tri-HELIX COMPLEX™ supplementation.

The clinical trial included 444 subjects divided into various groups: 53 elderly men (average age 72±5), 105 adult men aged 30–60, 77 premenopausal women aged 18–50, 57 young active men (average age 24±3), 30 recreationally active men averaging 25 years old, and 97 middle-aged untrained men aged 50±6. Each group received a daily dose of Tri-HELIX COMPLEX™ for 12 weeks.

Structured Training

Participants completed one hour of progressive resistance exercise training three times a week over 12 weeks.

Lean Mass Gains

Results confirmed increases in lean body mass, decreases in fat mass, reduced muscle loss in the elderly, and increased muscle strength.

Whole-Body Impact

The combination of supplementation and training supported healthier body composition across diverse participant groups.

Clinically Proven Reduction in Joint Pain & Stiffness

Improved mobility and comfort.

Clinical trials tested the effects of a daily dose of Tri-HELIX COMPLEX™ on the symptoms of osteoarthritis in elderly women.

6-Month Study

A randomized, double-blind, placebo-controlled study of 100 women aged 40–70 monitored joint health over six months.

Functional Improvements

Results showed significant decreases in joint pain and stiffness, plus improved joint function measured by the Lysholm score.

Rapid Symptom Relief

Womac scores (pain, stiffness, functional limitations) decreased rapidly during the course of the clinical trial.

Clinically Proven Reduction in OA Symptoms

Long-term osteoarthritis outcomes.

399 patients were randomised, aged 62 (35–84) years, 54% women, mean body mass index 27 (SD 4) kg/m², mean symptom duration 4 (SD 5) years, 0–100 normalised Lequesne Index 30 (SD 9) and global pain visual analogue scale 37 (SD 23) mm.

There were 20% fewer progressors in the ASU-E than in the placebo group (40% vs 50%, respectively, p=0.040). Safety was excellent.

Ready to learn more?

Speak with our team about Tri-HELIX COMPLEX™ trials and how these clinically tested results can support your wellness goals.

Add to Home Screen